Rochester, NY 8/27/2009 9:14:51 PM
Sinovac Biotech Ltd. SVA ,Sinovac Biotech Ltd. Raises H1N1 Vaccine Results
Sinovac Biotech Ltd.
Sinovac Biotech Ltd. announced that for fiscal August 19, 2009, anticipates sales to be higher than initial projections of $55 million to $60 million. Sinovac Biotech Ltd. proclaimed the positive top line results from the completed clinical trial for its internally developed H1N1 vaccine.
In Beijing, August 17, 2009 in the afternoon, clinical data unbinding conference was held. The analysis of the clinical trial results showed that the H1N1 vaccine developed by Sinovac induces good immunogenicity after one dose. The seropositive rate, seroconvertive rate and GMT increasing multiple have reached the international criteria for vaccines, which indicates that Sinovac's H1N1 vaccine has good immunogenicity and offers protection. After receiving one shot of the vaccine, none of the volunteers participating in Sinovac's clinical trials exhibited any signs of severe adverse reactions
About WhisperFromWallStreet
WhisperFromWallStreet.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified.
This is a free service available only to subscribers.Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://WhisperFromWallStreet.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither WhisperfromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers.
